Guidance

Medicines eligible for Northern Ireland MHRA Authorised Route

Sets out medicines that can be moved to Northern Ireland to meet patient need.

Documents

List of medicines that can be moved through NIMAR

Details

This document lists the medicines eligible for supply through the Northern Ireland MHRA Authorised Route (NIMAR).

From 1 January 2022, the listed medicines may be dispatched from Great Britain to Northern Ireland on the basis of the medicine’s authorisation in Great Britain.

This list is maintained and published in accordance with regulation 167B (list of NIMAR products) of the Human Medicines Regulations 2012 (SI 2012/1916, as amended).

Published 16 December 2021
Last updated 67 October 2022 + show all updates
  1. Updated the list to correct a dosage error: changed Secukinumab 300mg/2ml solution for injection pre-filled disposable devices to Secukinumab 150mg/1ml solution for injection pre-filled disposable devices.

  2. Added the following medicines to the list: Bimatoprost 300micrograms/ml eye drops 0.4ml unit dose preservative free; (Truxima 500mg/50ml concentrate for solution for infusion vials) Rituximab 500mg/50ml solution for infusion vials; and Secukinumab 300mg/2ml solution for injection pre-filled disposable devices. Changed Basiliximab 10mg powder and solvent for solution for injection vials (1 vial) to Simulect 10mg powder and solvent for solution for injection vials (1 vial) (brand to generic).

  3. Removed the ‘NutropinAq 10mg/2ml solution for injection cartridges’ brand name from the following generic medicines: Regadenoson 400micrograms/5ml solution for injection vials; Omalizumab 150mg/1ml solution for injection pre-filled syringes; Fondaparinux sodium 1.5mg/0.3ml solution for injection pre-filled syringes; Simulect 20mg powder and solvent for solution for injection vials; Enfuvirtide 108mg powder and solvent for solution for injection vials; Upadacitinib 45mg modified-release tablets.

  4. Added the following medicines: NutropinAq 10mg/2ml solution for injection cartridges (Enfuvirtide 108mg powder and solvent for solution for injection vials); NutropinAq 10mg/2ml solution for injection cartridges (Fondaparinux sodium 1.5mg/0.3ml solution for injection pre-filled syringes); NutropinAq 10mg/2ml solution for injection cartridges (Omalizumab 150mg/1ml solution for injection pre-filled syringes); NutropinAq 10mg/2ml solution for injection cartridges (Regadenoson 400micrograms/5ml solution for injection vials); NutropinAq 10mg/2ml solution for injection cartridges (Simulect 20mg powder and solvent for solution for injection vials); NutropinAq 10mg/2ml solution for injection cartridges (Somatropin (rbe) 10mg/2ml solution for injection cartridges); NutropinAq 10mg/2ml solution for injection cartridges (Upadacitinib 45mg modified-release tablets). Removed the following medicines: Fondaparinux sodium 10mg/0.8 ml solution for injection, pre-filled syringe; Fondaparinux sodium 7mg/0.6 ml solution for injection, pre-filled syringe; Fondaparinux sodium 5mg/0.4 ml solution for injection, pre-filled syringe.

  5. Updated the list of medicines that can be moved through NIMAR, adding the following: Basiliximab 10mg powder and solvent for solution for injection vials (1 vial), Suboxone 2mg/500microgram sublingual tablets, Suboxone 8mg/2mg sublingual tablets, Hemlibra 30mg/1ml solution for injection vials, Glycopyrronium 44 microgram inhalation powder capsules with device, Levemir Innolet 100 units/ml solution for injection 3ml pre-filled pens, Insulatard penfill 100 units/ml suspension for injection 3ml cartridges, Insulatard Innolet 100 units/ml suspension for injection 3ml pre-filled pens, Insulatard 100 units/ml suspension for injection 10ml vials, Metformin/vildagliptin 1000mg/50mg tablets, Metformin/vildagliptin 850mg/50mg tablets, Nepafenac 3mg/ml eye drops and Toremifine 60mg tablets.

  6. Added the following medicines: Epirubicin 200mg/100ml solution for infusion vials; Streptokinase 250,000 unit powder for solution for infusion vials; and Streptokinase 1.5 million unit powder for solution for infusion vials. Removed: Spectrila 10,000 units powder for solution for injection; Zirabev 100mg/4ml solution for infusion vials; Zykadia 150mg tablets; Xigduo 5mg/1000mg tablets; Xigduo 5mg/850mg tablets; Indivina 1mg/2.5mg tablets; Indivina 2mg/5mg tablets; Insuman Comb 50 100units/ml suspension for injection 3ml cartridges; Insulin isophane biphasic human 50/50 100units/ml suspension for injection 3ml cartridges; Ibrance 100mg tablets; Ibrance 125mg tablets; Ibrance 75mg tablets; Onpattro 2 mg/mL concentrate for solution for infusion; Somavert 20mg powder and solvent for solution for injection vials; Kisqali 200mg tablets; Ozempic 0.25mg/0.19ml solution for injection 1.5ml pre-filled pens; Ozempic 0.5mg/0.37ml solution for injection 1.5ml pre-filled pens; and Metalyse 10,000unit powder and solvent for solution for injection vials.

  7. Updated to remove 'Forxiga 10mg tablets' and 'Dapagliflozin 10mg tablets' from the list.

  8. Uploaded a corrected CSV attachment, adding: 'Topotecan 4mg/4ml concentrate for solution for infusion vials' and removing: 'Topotecan 4mg powder for solution for infusion vials'.

  9. Updated list of medicines. Removed: Topotecan 4mg/4ml concentrate for solution for infusion vials. Added: Spectrila 10,000 units powder for solution for injection; Asparginase 10,000 units powder for solution for injection; Xigduo 5mg/1000mg tablets; Dapagliflozin 5mg/Metformin 1g tablets; Xigduo 5mg/850mg tablets; Dapagliflozin 5mg/Metformin 850mg tablets; Forxiga 10mg tablets; Dapagliflozin 10mg tablets; Topotecan 4mg powder for solution for infusion vials.

  10. Updated the CSV file of medicines that can be moved through NIMAR. Adding: Cell-based quadrivalent influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-filled syringes; NeoRecormon 20,000units/0.6ml solution for injection pre-filled syringes; Epoetin beta 20,000units/0.6ml solution for injection pre-filled syringes; Ozempic 0.25mg/0.19ml solution for injection 1.5ml pre-filled pens; Semaglutide 0.25mg/0.19ml solution for injection 1.5ml pre-filled disposable device. Removing: Flucelvax Tetra vaccine suspension for injection 0.5ml pre-filled syringes; Influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-filled syringes.

  11. Added the following to the list of medicines that can be moved through NIMAR: Amlodipine/Valsartan 10mg/160mg, Amlodipine/Valsartan 5mg/160mg, Amlodipine/Valsartan 5mg/80gm, Fluorouracil 2.5g/100ml solution for infusion vials, Palbociclib 100mg tablets, Palbociclib 125mg tablets, Palbociclib 75mg tablets, Fluenz Tetra vaccine nasal suspension 0.2ml unit dose, Flucelvax Tetra vaccine suspension for injection 0.5ml pre-filled syringes, Ozempic 0.5mg/0.37ml solution for injection 1.5ml pre-filled pens, Imvanex vaccine suspension for injection 0.5ml vials, Metalyse 10,000unit powder and solvent for solution for injection vials, Topotecan 4mg powder for solution for infusion vials.

  12. Added the following to the list: Bevacizumab 100mg/4ml solution for infusion vials, Ceritinib 150mg tablets, Enbrel paediatric 10mg powder and solvent for injection vials, Estradiol valerate 1mg / Medroxyprogesterone 2.5mg tablets, Estradiol valerate 2mg / Medroxyprogesterone 5mg tablets, Etanercept 10mg powder and solvent for injection vials, Ibrance 75mg capsules, Ibrance 100mg capsules, Ibrance 125mg capsules, Indivina 1mg/2.5mg tablets, Indivina 2mg/5mg tablets, Kisqali 200mg tablets, Lapatinib 250mg tablets, Palbociclib 75mg capsules, Palbociclib 100mg capsules, Palbociclib 125 mg capsules, Pegvisomant 20mg powder and solvent for solution for injection vials, Ribociclib 200mg tablets , Somavert 20mg powder and solvent for solution for injection vials, Tyverb 250mg tablets (84 tablet), Zirabev 100mg/4ml solution for infusion vials and Zykadia 150mg tablets.

  13. Added to the list: Onpattro 2 mg/mL concentrate for solution for infusion; Patisiran 2 mg/mL concentrate for solution for infusion.

  14. Added Everolimus 3mg dispersible tablets sugar free, Nilotinib 150mg capsules, Pazopanib 200mg tablets, and Pazopanib 400mg tablets.

  15. Updated to remove Glucagon 0.5mg solution for injection in pre-filled pen from the list.

  16. Added Silver Sulfadiazine Cream 1%, Glucagon 0.5mg solution for injection in pre-filled pen, Glucagon 1mg solution for injection in pre-filled pen. Removed Estradiol 0.06% gel (750microgram per actuation).

  17. Replaced spreadsheet with updated version with the following listing: 'Fondaparinux sodium 7.5mg/0.6ml solution for injection, pre-filled syringe'.

  18. Added fondaparinux 5mg, 7mg and 10mg to the list of medicines that can be moved through NIMAR.

  19. Added bexarotene 75mg capsules to and removed eltrombopag 75mg capsules and thiopental from the list of medicines that can be moved through NIMAR.

  20. Replaced spreadsheet with updated version listing Buccolam as the brand name for Midazolam.

  21. Added Acetylcysteine, Canagliflozin, Eltrombopag, Estradiol, Insulin isophane, Midazolam, Progesterone and Topotecan to the list of medicines that can be moved through NIMAR.

  22. Added Etanercept 50mg/1ml, Somatropin (rbe) (5mg/1.5ml, 10mg/1.5ml, 15mg/1.5ml) and Thiopental 500mg powder to the list of medicines that can be moved through NIMAR.

  23. Added 'Cobimetinib 20mg tablets' to the list of medicines that can be moved through NIMAR.

  24. Added 2 new lines to the list: sodium chloride 0.18% + glucose 4% infusion bags and sucralfate 1g/5ml liquid.

  25. First published.